作者: Jonathan Welti , Sonja Loges , Stefanie Dimmeler , Peter Carmeliet
DOI: 10.1172/JCI70212
关键词: Angiogenic Proteins 、 Angiogenesis 、 Neovascularization 、 Fda approval 、 VEGF receptors 、 Cancer 、 Ocular neovascularization 、 Pharmacology 、 Biology 、 Antiangiogenic therapy 、 Cancer research
摘要: Four decades ago, angiogenesis was recognized as a therapeutic target for blocking cancer growth. Because of its importance, VEGF has been at the center stage antiangiogenic therapy. Now, several years after FDA approval an anti-VEGF antibody first agent, many patients with and ocular neovascularization have benefited from VEGF-targeted therapy; however, this anticancer strategy is challenged by insufficient efficacy, intrinsic refractoriness, resistance. Here, we examine recent discoveries new mechanisms underlying angiogenesis, discuss successes challenges current therapy, highlight emerging paradigms.